Adam assists life sciences and information technology companies navigate complex legal and business issues. With a practical and creative focus on his clients’ intended business results, he often functions as an outside general counsel and is regularly consulted by management teams for guidance on strategic matters. His clients are both public companies and emerging growth companies.
Adam has over twenty years of experience representing issuers and investment banks in connection with public and private financing transactions, SEC regulatory compliance and ’34 Act reporting. He also regularly represents buyers and sellers in mergers and acquisitions as well as corporations and limited liability companies with respect to general corporate issues that arise throughout the corporate life cycle--from formation to exit.
While an undergraduate at Yale, Adam played both football and baseball. He is also an avid bass fisherman.
Experience
Recent Representative Transactions
- Represented public life sciences company in a $50,000,000 follow on public offering.
- Represent public life sciences companies in connection with ’34 Act reporting and proxy matters
- Represented private life sciences company in a reverse merger into a Nasdaq listed public company.
- Represented public life sciences company in a $25,000,000 PIPE transaction.
- Represented private life sciences company in a $40,000,000 private equity financing.
- Represented private life sciences company in a $20,000,000 private equity financing.
- Represented private information technology company in a $8,830,000 preferred stock financing.
- Represented private information technology company in a $4,500,000 preferred stock financing.
- Represented private information technology company in a $28,000,000 preferred stock financing.
- Represented private information technology company in a $4,000,000 preferred stock financing.
- Represented private information technology company in a $5,000,000 venture debt transaction.
- Represented private information technology company in a stock-for-stock acquisition
- Represented private information technology company in a $1,250,000 convertible note financing.
- Represented private information technology company in a $900,000 convertible note financing.
- Represented private information technology company in a complex acquisition with earnout.
- Represented private green chemistry company in a $1,000,000 line of credit transaction.
- Represented private life sciences company in a $20,500,000 equity financing.
- Represented private information technology company in a $1,000,000 convertible note financing.
viewpoints
Life Sciences Newsletter — September 2021
September 1, 2021 | Article | By Adam Lenain, William Whelan, Jonathan L. Kravetz, Terri Shieh-Newton
Life Sciences Newsletter — October 2020
October 19, 2020 | Article | By Adam Lenain, William Whelan, Jonathan L. Kravetz, Terri Shieh-Newton
Life Sciences Newsletter — Inaugural Edition
August 20, 2020 | Article | By Adam Lenain, William Whelan, Jonathan L. Kravetz, Terri Shieh-Newton
News & Press
Biotechs get creative in hunt for money
February 22, 2018
Is Ephemeral Messaging an Evidence Foul? Not Necessarily
December 7, 2017
Events & Speaking
Recognition & Awards
Best Lawyers in America: Corporate Law (2021 – 2024); Biotechnology and Life Sciences Practice (2023-2024)
San Diego Business Journal Leaders in Law Winner (2020)
Order of the Coif
University of San Diego Law Review editor
University of San Diego School of Law merit scholarship recipient
Involvement
- Member, State Bar of California
- Member, San Diego County Bar Association
Recent Insights
Life Sciences Newsletter — September 2021
September 1, 2021| Article|
